Capital Market, Initial Public Offering and Medical

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

JANUARY 25, 2023

Newly public tech companies (particularly companies that went public via deSPAC transactions) may find themselves particularly in the crosshairs, given that they as a whole dramatically underperformed the broader market in 2022.

M&A

M&A Mergers and Acquisitions Private Equity Mergers

Investment Banking Today

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley’s 2022 Tech M&A Year in Review

Stay Connected